Literature DB >> 18852327

Liver is the site of splanchnic cortisol production in obese nondiabetic humans.

Rita Basu1, Ananda Basu, Meagan Grudzien, Paul Jung, Peer Jacobson, Michael Johnson, Ravinder Singh, Michael Sarr, Robert A Rizza.   

Abstract

OBJECTIVE: To determine the contribution of liver and viscera to splanchnic cortisol production in humans. RESEARCH DESIGN AND METHODS: D4 cortisol was infused intravenously; arterial, portal venous, and hepatic venous blood was sampled; and liver and visceral fat were biopsied in subjects undergoing bariatric surgery.
RESULTS: Ratios of arterial and portal vein D4 cortisol/cortisol(total) (0.06 +/- 0.01 vs. 0.06 +/- 0.01) and D4 cortisol/D3 cortisol (1.80 +/- 0.14 vs. 1.84 +/- 0.14) did not differ, indicating that no visceral cortisol production or conversion of D4 cortisol to D3 cortisol via 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) occurred. Conversely, ratios of both D4 cortisol to cortisol(total) (0.05 +/- 0.01; P < 0.05) and D4 cortisol to D3 cortisol (1.33 +/- 0.11; P < 0.001) were lower in the hepatic vein than in the portal vein, indicating production of both cortisol and D3 cortisol by the liver. The viscera did not produce either cortisol (-8.1 +/- 2.6 microg/min) or D3 cortisol (-0.2 +/- 0.1 microg/min). In contrast, the liver produced both cortisol (22.7 +/- 3.90 microg/min) and D3 cortisol (1.9 +/- 0.4 microg/min) and accounted for all splanchnic cortisol and D3 cortisol production. Additionally, 11beta-HSD-1 mRNA was approximately ninefold higher (P < 0.01) in liver than in visceral fat. Although 11beta-HSD-2 gene expression was very low in visceral fat, the viscera released cortisone (P < 0.001) and D3 cortisone (P < 0.01) into the portal vein.
CONCLUSIONS: The liver accounts for all splanchnic cortisol production in obese nondiabetic humans. In contrast, the viscera releases cortisone into the portal vein, thereby providing substrate for intrahepatic cortisol production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852327      PMCID: PMC2606891          DOI: 10.2337/db08-1079

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

1.  Splanchnic cortisol production in dogs occurs primarily in the liver: evidence for substantial hepatic specific 11beta hydroxysteroid dehydrogenase type 1 activity.

Authors:  Rita Basu; Dale S Edgerton; Ravinder J Singh; Alan Cherrington; Robert A Rizza
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

Review 2.  Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.

Authors:  J W Tomlinson; P M Stewart
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2001-03       Impact factor: 4.690

3.  A transgenic model of visceral obesity and the metabolic syndrome.

Authors:  H Masuzaki; J Paterson; H Shinyama; N M Morton; J J Mullins; J R Seckl; J S Flier
Journal:  Science       Date:  2001-12-07       Impact factor: 47.728

4.  Distinguishing the activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol.

Authors:  Ruth Andrew; Kenneth Smith; Gregory C Jones; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

5.  Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies.

Authors:  J S Moore; J P Monson; G Kaltsas; P Putignano; P J Wood; M C Sheppard; G M Besser; N F Taylor; P M Stewart
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

6.  The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.

Authors:  Ruth Andrew; Jukka Westerbacka; John Wahren; Hannele Yki-Järvinen; Brian R Walker
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

7.  Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.

Authors:  A Basu; R Basu; P Shah; A Vella; C M Johnson; K S Nair; M D Jensen; W F Schwenk; R A Rizza
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

Review 8.  Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes.

Authors:  M C Holmes; Y Kotelevtsev; J J Mullins; J R Seckl
Journal:  Mol Cell Endocrinol       Date:  2001-01-22       Impact factor: 4.102

9.  Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study.

Authors:  Odile Paulmyer-Lacroix; Sandrine Boullu; Charles Oliver; Marie-Christine Alessi; Michel Grino
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Tjeerd Barf; Jerk Vallgårda; Rikard Emond; Charlotta Häggström; Guido Kurz; Alf Nygren; Vivienne Larwood; Erifili Mosialou; Kent Axelsson; Rolf Olsson; Lars Engblom; Naimie Edling; Yuko Rönquist-Nii; Birgitta Ohman; Peteris Alberts; Lars Abrahmsén
Journal:  J Med Chem       Date:  2002-08-29       Impact factor: 7.446

View more
  28 in total

1.  G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome.

Authors:  Ibolya Czegle; Miklós Csala; József Mandl; Angelo Benedetti; István Karádi; Gábor Bánhegyi
Journal:  World J Hepatol       Date:  2012-04-27

2.  Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics.

Authors:  Xuewen Wang; Faidon Magkos; Bruce W Patterson; Dominic N Reeds; Janine Kampelman; Bettina Mittendorfer
Journal:  Eur J Endocrinol       Date:  2012-05-22       Impact factor: 6.664

3.  Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog.

Authors:  Dale S Edgerton; Rita Basu; Christopher J Ramnanan; Tiffany D Farmer; Doss Neal; Melanie Scott; Peer Jacobson; Robert A Rizza; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-16       Impact factor: 4.310

Review 4.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

5.  Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique.

Authors:  Simmi Dube; Barbara Norby; Vishwanath Pattan; Ravi K Lingineni; Ravinder J Singh; Rickey E Carter; Ananda Basu; Rita Basu
Journal:  Diabetologia       Date:  2014-04-26       Impact factor: 10.122

6.  Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis.

Authors:  J J Winnick; C J Ramnanan; V Saraswathi; J Roop; M Scott; P Jacobson; P Jung; R Basu; A D Cherrington; D S Edgerton
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-12       Impact factor: 4.310

7.  Glucocorticoid Excess Increases Hepatic 11β-HSD-1 Activity in Humans: Implications in Steroid-Induced Diabetes.

Authors:  Simmi Dube; Michael Q Slama; Ananda Basu; Robert A Rizza; Rita Basu
Journal:  J Clin Endocrinol Metab       Date:  2015-08-26       Impact factor: 5.958

8.  11β-hydroxysteroid dehydrogenase types 1 and 2 activity in subcutaneous adipose tissue in humans: implications in obesity and diabetes.

Authors:  Simmi Dube; Barbara J Norby; Vishwanath Pattan; Rickey E Carter; Ananda Basu; Rita Basu
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 9.  Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

10.  Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?

Authors:  Paul M Stewart; Jeremy W Tomlinson
Journal:  Diabetes       Date:  2009-01       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.